Abstract
New approaches to control tuberculosis (TB) worldwide are needed. In particular, new tools for diagnosis and new biomarkers are required to evaluate both pathogen and host key elements of the response to infection. Non-sputum based diagnostic tests, biomarkers predictive of adequate responsiveness to treatment, and biomarkers of risk of developing active TB disease are major goals. Here, we review the current state of the field. Although reports on new candidate biomarkers are numerous, validation and independent confirmation are rare. Efforts are needed to reduce the gap between the exploratory up-stream identification of candidate biomarkers, and the validation of biomarkers against clear clinical endpoints in different populations. This will need a major commitment from both scientists and funding bodies.
Reference163 articles.
1. http://www.who.int/tb/publications/global_report/en/
2. HIV infection-associated tuberculosis: the epidemiology and the response;Getahun;Clin Infect Dis,2010
3. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection;Selwyn;N Engl J Med,1989
4. Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence;Cantini;J Rheumatol Suppl,2014
5. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey;Cantini;Int J Rheum Dis,2015
Cited by
131 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献